Drug Shortage Report for EPIRUBICIN FOR INJECTION
Report ID | 194144 |
Drug Identification Number | 02324091 |
Brand name | EPIRUBICIN FOR INJECTION |
Common or Proper name | EPIRUBICIN FOR INJECTION |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | EPIRUBICIN HYDROCHLORIDE |
Strength(s) | 2MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 25ML |
ATC code | L01DB |
ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-06-08 |
Estimated end date | 2023-09-20 |
Actual end date | 2023-09-30 |
Shortage status | Resolved |
Updated date | 2023-10-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v11 | 2023-10-03 | French | Compare |
v10 | 2023-10-03 | English | Compare |
v9 | 2023-07-19 | French | Compare |
v8 | 2023-07-19 | English | Compare |
v7 | 2023-06-27 | French | Compare |
v6 | 2023-06-27 | French | Compare |
v5 | 2023-06-27 | English | Compare |
v4 | 2023-06-09 | English | Compare |
v3 | 2023-06-08 | French | Compare |
v2 | 2023-06-08 | English | Compare |
v1 | 2023-06-08 | English | Compare |
Showing 1 to 11 of 11